IHS Scientific Meeting

27 Jun 2007 07:01

Minster Pharmaceuticals PLC27 June 2007 For immediate release 27 June 2007 MINSTER PHARMACEUTICALS PLC ("Minster" or "the Company") Presentation at the 13th Congress of the International Headache Society Minster Pharmaceuticals plc (AIM: MPM), the drug development companyspecialising in neurological and psychiatric disorders, is pleased to announcethat Professor Peter Goadsby, the principal investigator in the Company's recentclinical trial of tonabersat in the prevention of migraine, will deliver apresentation on Saturday 30 June 2007 at the 13th Congress of the InternationalHeadache Society in Stockholm, Sweden. The presentation by Prof Goadsby, who is Professor of Neurology at the Instituteof Neurology in London, will discuss the positive trial data from a Phase IIastudy of tonabersat in the prevention of migraine, the initial findings fromwhich were announced earlier this year. Prof Goadsby's presentation has beenallocated one of the small number of opportunities on the agenda reserved forsignificant late-breaking news. Further details about the International Headache Society meeting are availablefrom the organisation's website, www.ihc2007.org. For further information: Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623 Paul Sharpe, Chief Executive OfficerRobert Aubrey, Chief Financial Officer Buchanan Communications Tel: +44 (0) 20 7466 5000 Mark Court/Rebecca Skye Dietrich/Catherine Breen Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200 Chris Collins/Richard Potts Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals is a drug development company focussed on neurologicaland psychiatric disorders. Its principal pipeline assets are tonabersat, underdevelopment in the preventive treatment of migraine, and sabcomeline inschizophrenia. Worldwide rights to both compounds were acquired fromGlaxoSmithKline and the compounds benefit from comprehensive safety tolerancedata as a result of investment by GSK. Tonabersat is the most advanced compound in an exciting new class of drugscalled gap junction blockers, which have significant potential in the preventionof migraine and other major neurological conditions. Sabcomeline, a muscarinicpartial agonist, has potential in the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialisation of itscurrent pipeline. Its medium term strategy is to leverage the anticipatedcashflows from the current pipeline by in-licensing further compounds with theultimate objective of creating a substantial and highly efficient drugdevelopment enterprise focussed on the central nervous system. Minster joined the AIM market in February 2005 and trades under the symbol MPM.For further information please visit www.minsterpharma.com. This information is provided by RNS The company news service from the London Stock Exchange